Dr Marcela Maus

Clinical trial results from show "dramatic & rapid" regression of glioblastoma after next generation CAR T therapy at the @MGHCancerCenter with @MarcelaMaus, MD, director of the Cellular Immunotherapy Program. Learn more: spklr.io/6011Wf0l @NEJM

Today, @NEJM published our clinical study of a novel #CARTCell in patients with #Glioblastoma. Early results with CARv3-TEAM-E suggest safety and bioactivity. Special thanks to all collaborators @MGHNeurosurg and @MGHCancerCenter! nej.md/3VnjUIq

High antigen density of BCMA: friend or foe to CAR T cells? jitc.bmj.com/content/10/9/e…

Not all people respond equally well to CAR-T cell therapy, a kind of immunotherapy that has dramatically improved blood cancer treatment. A new single-cell study by researchers at the Broad, @MassGeneralNews, and @DanaFarber could help reveal why. broad.io/carttherapy0912

A collaborative team at the @broadinstitute describes distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell #lymphoma. 🥼 @MarcelaMaus @gaddyg @Mark_Leick @Dr_KatieM @SatyenGohil Learn more: go.nature.com/3eQtbWc

.@MassGeneralNews researchers, led by ASGCT Board Member @MarcelaMaus & Associate Member @Mark_Leick, developed a novel treatment strategy that has the potential to bring the benefits of #CART #celltherapy to patients with acute myeloid #leukemia (#AML). bit.ly/3kq9JPP

@drkomanduri @Mark_Leick Thanks!

Congrats @MarcelaMaus and @Mark_Leick!

Exciting new CAR design for AML from our lab! Now online @Cancer_Cell @MGHCancerCenter @MGBInnovation

Delighted to share our work optimizing CAR-T cells for acute myeloid leukemia. We're working rapidly on this devastating disease and will be presenting our dual targeting strategy building on this publication in May @ASGCT in Washington DC @Cancer_Cell cell.com/cancer-cell/fu…

@PatrickHwuMD thank you, Patrick!

Outstanding work by the Maus lab demonstrating how #glioblastoma can escape CAR T cells. Defects in the interferon gamma pathway in the glioblastoma cells can make them less “sticky” so the CAR T cells cannot bind to and kill them. @MarcelaMaus nature.com/articles/s4158…

@hereisramji @SchmidtsAndrea @Nature thanks!

@SchmidtsAndrea @Nature @MarcelaMaus Very good session at aacr

How do CAR-T cells kill tumor cells? - It depends… Exciting work @Nature by @MarcelaMaus Rebecca Larson & colleagues on the role of IFNg signaling in CAR-T mediated killing. Congrats to the entire team! nature.com/articles/s4158…

@jameslriley @celltherapynews @Nature @harvardmed hahaha, you know my secrets outside the zoom box

@celltherapynews @Nature @MarcelaMaus @harvardmed Nice picture (and paper)...way to make it look like you are sitting when I know you are really standing to use the hood @MarcelaMaus

✨ New today in @Nature! Dr. @MarcelaMaus at @harvardmed and colleagues demonstrated that liquid 💧 and solid 🧊 tumors differ in their interactions with #CAR T cells, particularly in regards to the IFNγR pathway. go.nature.com/3xr4bfz

Saw @Marcelamaus present this at #AACR2022 - really beautiful story! congrats.

Critical findings from a study @Nature led by @MarcelaMaus differentiating CAR T-cell efficacy against liquid versus solid tumors like #Glioblastoma ...INFg is the key! nature.com/articles/s4158…

Online at @nature: “CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours” by @MarcelaMaus and colleagues nature.com/articles/s4158…

Today #AACR22, don’t miss @njharlen presenting on single-cell analysis of cellular dynamics underlying clinical response to #CARTcell therapy in #collab work with Cathy Wu and @MarcelaMaus labs (Talk #3575). Then, read more of the story @medrxiv: medrxiv.org/content/10.110…

Mechanisms of CAR T-cell therapy + #immunotherapy being discussed today at #AACR22 by @StBaldricks @SU2C #PediatricCancer Dream Team Co-leader Dr. Crystal Mackall + Innovative Rsch Grant Recipient @MarcelaMaus @MackallLab @StanfordCancer @MassGeneralNews abstractsonline.com/pp8/#!/10517/s…

Excited to share the latest work from my PhD! We performed the first CRISPR activation screen to identify genes that drive solid tumor resistance to T cell-mediated cytotoxicity. A thread 1/X nature.com/articles/s4146…